Absci Corporation’s ABSI share price has dipped by 5.12%, which has investors questioning if this is right time to buy.

Washington’s life sciences industry injected a $41.2-billion impact into the state’s economy in 2023 — a 6.2% gain over 2022 ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Absci Corp. research and ratings by Barron's. View ABSI revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Shares of NASDAQ ABSI opened at $3.09 on Wednesday. Absci has a 52 week low of $2.01 and a 52 week high of $6.33. The company has a quick ratio of 5.63, a current ratio of 5.63 and a debt-to ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

WASHINGTON — The Trump administration has been accused of ignoring or flat-out defying recent federal court orders, with two judges now weighing contempt findings against officials. Washington ...

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech ...

KeyBanc raised the firm’s price target on Absci (ABSI) to $9 from $5 and keeps an Overweight rating on the shares. Into Q1 earnings, the firm believes the focus for the HCIT sector will be on ...